医学と薬学　80/3　2023年3月号

出版社： 自然科学社
発行日： 2023-02-27
分野： 薬学  >  雑誌
ISSN： 03893898
雑誌名：
特集： 甲状腺癌
電子書籍版： 2023-02-27 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

1,540 円(税込)

購入する

目次

  • 特集　甲状腺癌

    序文
    甲状腺癌の超音波所見
    甲状腺癌の外科治療
    　―アクティブサーベイランスも含めて
    甲状腺癌の内科治療
    甲状腺癌取扱い規約とWHO分類
    甲状腺癌と遺伝子異常
    福島県原子力発電所事故後における小児・若年者甲状腺癌

    Diagnosis
    　唾液および鼻咽頭ぬぐい液を適用検体とする
    　　新型コロナウイルス検出迅速抗原検査キットの評価
    「LZテスト‘栄研’CRP-RV」の臨床化学自動分析装置への適応検討

    Health Care
    「リライブシャツ・パンツ」の着用が体組成および身体機能へ与える影響
    　　―二重盲検化比較対照試験―
    　ダニがヒトに与える影響と対策

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【特集 甲状腺癌】

P.238 掲載の参考文献
1) Tunbrige WM, Evered DC, Hall R, et al:The spectrum of thyroid disease in a community:The Whickham survey. Clin Endocrinol(Oxf) 7:481-493, 1977.
 
2) Hegediis L:Clinical practice. The thyroid nodule. N Engl J Med 351:1764-1771, 2004.
 
3) Ezzat S, Sarti DA, Cain DR, et al:Thyroid incidentalomas:Prevalence by palpitation and ultrasonography. Arch Intern Med 154:1838-1840, 1994.
 
4) Gnarini VL, Brigante G, Della et al:Very high prevalence of ultrasound thyroid scan abnor-malities in healthy volunteers in Modena, Italy. J Endocrinol Invest 36:722-728, 2013.
 
5) Guth S, Theune U, Aberle J, et al:Very high prevalence of thyroid nodules detected by high frequency(13 MHz) ultrasound examination. Eur J Clin Invest 39:699-706, 2009.
PubMed
6) Papini E, Guglielmi R, Bianchini A, et al:Risk of malignancy in nonpalpable thyroid nodules:predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab 87:1941-1946. 2002.
PubMed
7) Nam-Goong IS, Kim HY, Gong G, et al:Ultra-sonography-guided fine-needle aspiration of thyroid incidentaloma:correlation with patholog-ical findings. Clin Endocrinol (Oxf) 60:21-28, 2004.
 
8) 日本内分泌外科学会・日本甲状腺病理学会(編):甲状腺癌取扱い規約第8版.金原出版, 東京, 2019.
 
9) 日本乳腺甲状腺超音波医学会甲状腺用語診断基準委員会(編):甲状腺超音波診断ガイドブック改定第3版. 南江堂, 東京, 2016.
 
10) 日本超音波医学会用語・診断基準委員会:甲状腺結節(腫瘤)超音波診断基準. 超音波医 38:667-668, 2011.
 
11) Fukushima M, Fukunari N, Murakami T, et al:Reconfirmation of the accuracy of the taller-than-wide sign in multicenter collaborative research in Japan. Endocr J 68:897-904, 2021.
PubMed
12) Fukunari N, Nagahama M, Sugino K, et al:Clin-ical evaluation of color doppler imaging for the differential diagnosis of thyroid follicular lesions. World J Surg 28:1261-1265, 2004.
 
13) Miyakawa M, Onoda N, Etoh M, et al:Diagnosis of thyroid follicular carcinoma by the vascular pattern and velocimetric parameters using high resolution pulsed and power Doppler ultrasonog-raphy. Endocr J 52:207-212, 2005.
 
14) Saller B, Moeller L, Gorges R et al:Role of con-ventional ultrasound and color doppler sonography in the diagnosis of medullary thyroid carcinoma. Exp Clin Endocrionol Diabetes 110:403-407, 2002.
 
15) Simcic KJ, Bowland WF:Cystic medullay thyroid cancer. Surgery 117:356-357, 1995.
 
16) Ota H, Ito Y, Matsuzaka F et al:Usefulness of ultrasonography for diagnosis of malignant lym-phoma of the thyroid. Thyroid 16:983-987, 2006.
 
P.246 掲載の参考文献
1) 日本内分泌外科学会・日本甲状腺外科学会:甲状腺腫瘍診療ガイドライン2018. 日内分泌・甲状腺外会誌 35(Suppl 3), 2018.
 
2) 日本内分泌外科学会 甲状腺微小癌取扱い委員会(編):成人の甲状腺低リスク微小乳頭癌T1aN0M0に対する積極的経過観察の適応と方法:日本内分泌外科学会 甲状腺微小癌取扱い委員会による提言. 日内分泌外会誌 37:292-309, 2020.
 
P.255 掲載の参考文献
1) Brose MS, Nutting CM, Jarzab B, et al:Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer:a ran-domised, double-blind, phase 3 trial. The Lancet 384:319-328, 2014.
PubMed
2) Ito Y, Onoda N, Ito KI, et al:Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma. Thyroid 27:1142-1148, 2017.
PubMed
3) Schlumberger M, Tahara M, Wirth LJ, et al:Len-vatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372:621-630, 2015.
 
4) Takahashi S, Kiyota N, Yamazaki T, et al:A Phase II study of the safety and efficacy of len-vatinib in patients with advanced thyroid cancer. Future Oncol 15:717-726, 2019.
 
5) Tahara M, Kiyota N, Yamazaki T, et al:Lenvati-nib for Anaplastic Thyroid Cancer. Front Oncol 7:25, 2017.
PubMed
6) Higashiyama T, Sugino K, Hara H, et al:Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer(HOPE). Eur J Cancer 173:210-218, 2022.
PubMed
7) Wells SA Jr., Robinson BG, Gagel RF, et al:Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer:a rand-omized, double-blind phase III trial. J Clin Oncol 30:134-141, 2012.
PubMed
8) Zehir A, Benayed R, Shah RH, et al:Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 23:703-713, 2017.
PubMed
9) Network NCC:NCCN Guidelines(R) for Thyroid Carcinoma, version 2.2022, 2022.
 
10) Elisei R, Tacito A, Ramone T, et al:Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC:An Update on The Prevalence of Germline RET Mutations. Genes(Basel) 10:698, 2019.
PubMed
11) Cancer Genome Atlas Research N:Integrated genomic characterization of papillary thyroid car-cinoma. Cell 159:676-690, 2014.
 
12) Wirth LJ, Sherman E, Robinson B, et al:Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med 383:825-835, 2020.
PubMed
13) Subbiah V, Hu MI, Wirth LJ, et al:Pralsetinib for patients with advanced or metastatic RET-al-tered thyroid cancer(ARROW):a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol 9:491-501, 2021.
PubMed
14) Forsythe A, Zhang W, Phillip Strauss U, et al:A systematic review and meta-analysis of neu-rotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors. Ther Adv Med Oncol 12:1758835920975613, 2020.
 
15) Demetri GD, De Braud F, Drilon A, et al:Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. Clin Cancer Res 28:1302-1312, 2022.
PubMed
16) Waguespack SG, Drilon A, Lin JJ, et al:Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endo-crinol 186:631-643, 2022.
 
17) Marabelle A, Fakih M, Lopez J, et al:Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab:prospective biomarker analysis of the multicohort, open-label, phase 2 KEY-NOTE-158 study. Lancet Oncol 21:1353-1365, 2020.
 
18) Akagi K, Oki E, Taniguchi H, et al:Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors. Cancer Sci 112:1105-1113, 2021.
 
19) Maio M, Ascierto PA, Manzyuk L, et al:Pem-brolizumab in microsatellite instability high or mismatch repair deficient cancers:updated analy-sis from the phase II KEYNOTE-158 study. Ann Oncol 33:929-938, 2022.
 
20) Ito Y, Yoshida H, Kihara M, et al:BRAF(V600E) mutation analysis in papillary thyroid carcinoma:is it useful for all patients? World J Surg 38:679-687, 2014.
PubMed
21) Xing M, Alzahrani AS, Carson KA, et al:Asso-ciation between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol 33:42-50, 2015.
 
22) Busaidy NL, Konda B, Wei L, et al:Dab-rafenib Versus Dabrafenib+Trametinib in <i>BRAF</i>-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer:Results of a Randomized, Phase 2, Open-Label Multicenter Trial. Thyroid 32:1184-1192, 2022.
 
23) Subbiah V, Kreitman RJ, Wainberg ZA, et al:Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer:updated analysis from the phase II ROAR basket study. Ann Oncol 33:406-415, 2022.
PubMed
24) Brose MS, Cabanillas ME, Cohen EE, et al:Vemurafenib in patients with BRAF(V600E) -positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine:a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol 17:1272-1282, 2016.
PubMed
25) Kelly LM, Barila G, Liu P, et al:Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thy-roid cancer. Proc Natl Acad Sci USA 111:4233-4238, 2014.
 
26) Demeure MJ, Aziz M, Rosenberg R, et al:Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer iden-tified EML4-ALK translocation as a therapeutic target. World J Surg 38:1296-1305, 2014.
 
27) Leroy L, Bonhomme B, Le Moulec S, et al:Remarkable Response to Ceritinib and Brigatinib in an Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma Previously Treated with Crizotinib. Thyroid 30:343-344, 2020.
 
28) Prior IA, Hood FE, Hartley JL:The Frequency of Ras Mutations in Cancer. Cancer Res 80:2969-2974, 2020.
PubMed
29) 厚生労働省:患者申出療養制度. https://www.mhlw.go.jp/moushideryouyou/professional.html.
 
30) Miyauchi A, Kudo T, Miya A, et al:Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid 21:707-716, 2011.
PubMed
31) Ito Y, Onoda N, Kudo T, et al:Sorafenib and Lenvatinib Treatment for Metastasis/Recurrence of Radioactive Iodine-refractory Differentiated Thyroid Carcinoma. In Vivo 35:1057-1064, 2021.
PubMed
32) Brose MS, Worden FP, Newbold KL, et al:Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial. J Clin Oncol 35:2692-2699, 2017.
 
33) Tahara M, Kiyota N, Hoff AO, et al:Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radi-oiodine-refractory differentiated thyroid cancer. Eur J Cancer 147:51-57, 2021.
 
34) Kiyota N, Tahara M, Robinson B, et al :Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differenti-ated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial. Cancer 128:2281-2287, 2022.
 
35) Kiyota N, Schlumberger M, Muro K, et al:Sub-group analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory dif-ferentiated thyroid cancer. Cancer Sci 106:1714-1721, 2015.
 
36) Enokida T, Tahara M:Management of VEG-FR-Targeted TKI for Thyroid Cancer. Cancers(Basel) 13:5536, 2021.
 
37) Tahara M, Brose MS, Wirth LJ, et al:Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refrac-tory differentiated thyroid cancer. Eur J Cancer 106:61-68, 2019.
 
38) Tahara M, Takami H, Ito Y, et al:Planned drug holiday in a cohort study exploring the effect of lenvatinib on differentiated thyroid cancer. J Clin Oncol 39(suppl 15):6070-6070, 2021.
 
P.266 掲載の参考文献
1) WHO Classification of Tumours Editorial Board. Endocrine and Neuroendocrine tumours. Lyon(France):International Agency for Research on Cancer, 2022. https://tumourclassification.iarc.who.int/chapters/36.
 
2) Jung CK, Bychkov A, Kakudo K:Update from the 2022 WHO Classification of Thyroid Tumors:A Standardized Diagnostic Approach. Endocrinol Metab (Accepted for publication).
 
3) 日本内分泌外科・日本甲状腺病理学会 編:甲状腺癌取扱い規約 第8版, 金原出版, 東京, 2019.
 
4) Welch HG, Black WC:Overdiagnosis in cancer. J Natl Cancer Inst 102:605-613, 2010.
 
5) Davies L, Welch HG:Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 140:317-322, 2014.
PubMed
6) Ahn HS, Kim HJ, Welch HG:Korea's thyroid-can-cer "epidemic"-screening and overdiagnosis. N Engl J Med 371:1765-1767, 2014.
 
7) Esserman LJ, Thompson IM, Reid B, et al:Addressing overdiagnosis and overtreatment in cancer:a prescription for change. Lancet Oncol 15:e234-242, 2014.
 
8) Welch HG, Doherty GM:Saving Thyroids-Overtreatment of Small Papillary Cancers. N Engl J Med 379:310-312, 2018.
PubMed
9) Kakudo K, Wakasa T, Ohta Y, et al:Prognostic classification of follicular cell tumors using Ki-67 labeling index:Risk stratification of thyroid folli-cular cell carcinoma. Endcr J 62:1-12, 2015.
 
10) Kakudo K, Liu Z, Bai Y, et al:How to identify indolent thyroid tumors unlikely to recur and cause cancer death immediately after surgery-Risk stratification of papillary thyroid carcinoma in young patients. Endocr J 68:871-880, 2021.
PubMed
11) Kakudo K, Takano T:Chapter 9:Proportion of clinically insignificant papillary thyroid carcinoma and self-limiting carcinoma that does not harm patients. (submitted for publication in the 3rd edition Thyroid FNA Cytology;Differential Diag-noses and Pitfalls, Springer)
 
12) Hiltzik D, Carlson DL, Tuttle RM, et al:Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis:a clinicopathologic study of 58 patients. Cancer 106:1286-1295, 2006.
PubMed
13) Baloch ZW, Asa SL, Barletta JA, et al:Overview of the 2022 WHO Classification of Thyroid Neo-plasms. Endocr Pathol 33:27-63, 2022.
 
14) Sakamoto A, Kasai N, Sugano H:Poorly differen-tiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and folli-cular carcinomas. Cancer 52:1849-1855, 1983.
 
15) Kakudo K, Miyauchi A, Katayama S, et al:Ultra-structural study of poorly differentiated medullary carcinoma of the thyroid. Virchows Arch A Pathol Anat Histopathol 410:455-460, 1987.
 
16) Kakudo K:C cell disease of the thyroid. Subclas-sification and prognostic factors of medullary (C cell) carcinoma of the thyroid (eds. by Lechango, J, Kameya, T), pp.85-97, Field & Wood Medical Publishers, Philadelphia, 1990.
 
17) 伊藤康弘, 宮内 昭:分化癌取扱いの変更点. 内分泌外科学会雑誌 38:18-22, 2021.
 
18) 藤原正親, 菅間 博:第8版甲状腺癌取扱い規約における第4版WHO分類の境界悪性腫瘍の取扱い. 内分泌外科学会雑誌 38:23-27, 2021.
 
19) Hay ID:Managing patients with a preoperative diagnosis of AJCC/UICC stage I (T1N0M0) pap-illary thyroid carcinoma:East versus West, whose policy is best? World J Surg 34:1291-1293, 2010.
 
20) Takami H, Ito Y, Okamoto T, et al:Revisiting the guidelines issued by the Japanese Society of Thy-roid Surgeons and Japan Association of Endocrine Surgeons:a gradual move towards consensus between Japanese and western practice in the management of thyroid carcinoma. World J Surg 38:2002-2010, 2014.
 
21) Kakudo K, Higuchi M, Hirokawa M, et al:Thy-roid FNA cytology in Asian practice-Active surveillance for indeterminate thyroid nodules reduces overtreatment of thyroid carcinomas. Cytopathology 28:455-466, 2017.
 
22) Kakudo K:Asian and Western practice in thyroid pathology:Similarities and differences. Gland Surg 9:1614-1627, 2020.
PubMed
23) Ito Y, Onoda N, Okamoto T:The revised clinical practice guidelines on the management of thyroid tumors by the Japan Associations of Endocrine Surgeons:Core questions and recommendations for treatments of thyroid cancer. Endocr J 67:669-717, 2020.
PubMed
24) Kakudo K, Katoh R, Sakamoto A, et al:Thy-roid gland:international case conference. Endocr Pathol 13:131-134, 2002.
 
25) Hirokawa M, Carney JA, Goellner JR, et al:Observer variation of encapsulated follicular lesions of the thyroid gland. Am J Surg Pathol 26:1508-1514, 2002.
PubMed
26) Lloyd RV, Erickson LA, Casey MB, et al:Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 28:1336-1340, 2004.
PubMed
27) Poller DN, Cochand-Priollet B, Trimboli P:Thyroid FNA terminology:The case for a sin-gle unified international system for thyroid FNA reporting. Cytopathology 32:714-717, 2021.
 
28) Glomski K, Nose V, Faquin WC, et al:Metastatic Follicular Thyroid Carcinoma and the Primary Thyroid Gross Examination:Institutional Review of Cases from 1990 to 2015. Endocr Pathol 28:177-185, 2017.
PubMed
29) Kakudo K, Bai Y, Liu Z, et al:Classification of thyroid follicular cell tumors:with special refer-ence to borderline lesions. Endocr J 59:1-12, 2012.
 
30) Lloyd RV, Osamura RY, Kloppel G, et al(eds):WHO Classification of Tumours of Endocrine Organs, WHO Classification of Tumours, 4th Edi-tion, Volume 10, IARC, Lyon, 2017.
 
31) Carney JA, Ryan J, Goellner JR:Hyalinizing tra-becular adenoma of the thyroid gland. Am J Surg Pathol 11:583-591, 1987.
 
32) Carney JA, Hirokawa M, Lloyd RV, et al:Hyalin-izing trabecular tumors of the thyroid gland are almost all benign. Am J Surg Pathol 32:1877-1889, 2008.
 
33) Bai Y, Kakudo K, Li Y, et al:Subclassification of non-solid-type papillary thyroid carcinoma identification of high-risk group in common type. Cancer Sci 99:1908-1915, 2008.
PubMed
34) Piana S, Frasoldati A, Di Felice E, et al:Encap-sulated well-differentiated follicular-patterned thyroid carcinomas do not play a significant role in the fatality rates from thyroid carcinoma. Am J Surg Pathol 34:868-872, 2010.
 
35) Giani C, Torregrossa L, Ramone T, et al:Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer. J Clin Endocrinol Metab 106:e4072-e4083, 2021.
PubMed
36) Rivera M, Ricarte-Filho J, Patel S, et al:Encap-sulated thyroid tumors of follicular cell origin with high grade features (high mitotic rate/tumor necrosis):a clinicopathologic and molecular study. Hum Pathol 41:172-180, 2010.
 
37) Kakudo K, Bai Y, Katayama S, et al:Classifica-tion of follicular cell tumors of the thyroid gland:analysis involving Japanese patients from one institute. Pathol Int 59:359-367, 2009.
 
38) Marcadis AR, Marti JL, Ehdaie B, et al:Char-acterizing Relative and Disease-Specific Survival in Early-Stage Cancers. JAMA Intern Med 180:461-463, 2020.
 
P.274 掲載の参考文献
1) WHO Classification of Tumours Editorial Board:Endocrine and Neuroendocrine tumours[Inter-net]. WHO 5th Classification of Endocrine tumors, IARC, Lyon, 2022.
 
2) 国立がん研究センター:がん情報サービス, がん種別統計情報 甲状腺. https://ganjoho.jp/reg_stat/statistics/stat/cancer/24_thyroid.html
 
3) Hirokawa M, Carney JA, Goellner JR, et al:Observer variation of encapsulated follicular lesions of the thyroid gland. Am J Surg Pathol 26:1508-1514, 2002.
PubMed
4) Nikiforov YE, Seethala RR, Tallini G, et al:Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma:a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol 2:1023-1029, 2016.
PubMed
5) Sugitani I, Ito Y, Takeuchi D, et al:Indications and Strategy for Active Surveillance of Adult Low-Risk Papillary Thyroid Microcarcinoma:Consensus Statements from the Japan Association of Endocrine Surgery Task Force on Management for Papillary Thyroid Microcarcinoma. Thyroid 31:183-192, 2021.
PubMed
6) Thomas GA, Bunnell H, Cook HA, et al:High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas:a strong correlation between RET/PTC3 and the solid-follicular variant. J Clin Endocrinol Metab 84:4232-4238, 1999.
 
7) Mitsutake N, Fukushima T, Matsuse M, et al:BRAF (V600E) mutation is highly prevalent in thyroid carcinomas in the young population in Fukushima:a different oncogenic profile from Chernobyl. Sci Rep 5:16976, 2015.
 
8) Alexandrov LB, Nik-Zainal N, Wedge DC, et al:Signatures of mutational processes in human can-cer. Nature 500:415-421, 2013.
 
9) Baloch Z, Asa S, Barlett JA, et al:Overview of the 2022 WHO Classification of Thyroid Neo-plasms. End Pathology 33:27-63, 2022.
 
10) 千葉知宏, 住石 歩, 菅間 博:甲状腺腫瘍WHO分類の背景にある病理診断の特異性と遺伝子変異. 日内分泌・甲状腺外会誌 36:146-150, 2019
 
P.279 掲載の参考文献
1) United Nations Scientific Committee on the Effects of Atomic Radiation:Scientific Annex B, UNS CEAR 2020 Report, 2020. http://www.unscear.org/docs/publications/2020/UNSCEAR_2020_AnnexB_AdvanceCopy.pdf
 
2) Ishikawa T, Yasumura S, Ozasa K, et al:The Fukushima Health Management Survey:estima-tion of external doses to residents in Fukushima Prefecture. Sci Rep 5:12712, 2015.
 
3) Ohba T, Ishikawa T, Nagai H, et al:Reconstruc-tion of residents' thyroid equivalent doses from internal radionuclides after the Fukushima Daiichi nuclear power station accident. Sci Rep 10:3639, 2020.
 
4) Yasumura S, Ohira T, Ishikawa T, et al:Achievements and Current Status of the Fukus-hima Health Management Survey. J Epidemiol 32(Supplement_XII):S3-S10, 2022.
 
5) Shimura H, Suzuki S, Yokoya S, et al:A Compre-hensive Review of the Progress and Evaluation of the Thyroid Ultrasound Examination Program, the Fukushima Health Management Survey. J Epidemiol 32(Supple XII):S23-S35, 2022.
 
6) 貴田岡正史, 宮本幸夫, 福成信博, 他:甲状腺結節(腫瘤)超音波診断基準. 超音波医学 38:667-670, 2011.
 
7) 鈴木眞一:V. 診断の進め方, C. 結節性病変. 日本乳腺甲状腺超音波医学会 甲状腺用語診断基準委員会(編):甲状腺超音波診断ガイドブック改訂第3版, pp.48-53, 南江堂, 東京, 2016.
 
8) Shimura H, Matsumoto Y, Murakami T, et al:Diagnostic Strategies for Thyroid Nodules Based on Ultrasonographic Findings in Japan. Cancers(Basel)13:4629, 2021.
PubMed
9) 福島県県民健康調査検討委員会:第46回「県民健康調査」検討委員会(令和4年12月2日)の資料について, 2022.https://www.pref.fukushima.lg.jp/site/portal/kenkocyosa-kentoiinkai-46.html
 
10) Nakaya T, Takahashi K, Takahashi H, et al:Spa-tial analysis of the geographical distribution of thyroid cancer cases from the first-round thyroid ultrasound examination in Fukushima Prefecture. Sci Rep 8:17661, 2018.
 
11) Nakaya T, Takahashi K, Takahashi H, et al:Re-visiting the Geographical Distribution of Thyroid Cancer Incidence in Fukushima Prefecture:Anal-ysis of Data From the Second- and Third-round Thyroid Ultrasound Examination. J Epidemiol 32(Suppl XII):S76-S83, 2022.
 
12) Ohira T, Takahashi H, Yasumura S, et al:Com-parison of childhood thyroid cancer prevalence among 3 areas based on external radiation dose after the Fukushima Daiichi nuclear power plant accident:The Fukushima health management survey. Medicine(Baltimore) 95:e4472, 2016.
 
13) Ohira T, Takahashi H, Yasumura S, et al:Asso-ciations Between Childhood Thyroid Cancer and External Radiation Dose After the Fukushima Daiichi Nuclear Power Plant Accident. Epidemiol-ogy 29:e32-e34, 2018.
 
14) Ohira T, Ohtsuru A, Midorikawa S, et al:Exter-nal Radiation Dose, Obesity, and Risk of Childhood Thyroid Cancer After the Fukushima Daiichi Nuclear Power Plant Accident:The Fukushima Health Management Survey. Epidemiology 30:853-860, 2019.
 
15) Ohira T, Shimura H, Hayashi F, et al:Absorbed radiation doses in the thyroid as estimated by UNSCEAR and subsequent risk of childhood thyroid cancer following the Great East Japan Earthquake. J Radiat Res 61:243-248, 2020.
PubMed
16) 福島県県民健康調査検討委員会:県民健康調査における中間取りまとめ, 2016. https://www.pref.fukushima.lg.jp/uploaded/attachment/158522.pdf
 
17) 福島県県民健康調査検討委員会:第36回「県民健康調査」検討委員会の資料について, 2019. https://www.pref.fukushima.lg.jp/site/portal/kenkocyosa-kentoiinkai-36.html
 
18) Suzuki S, Bogdanova TI, Saenko VA, et al:Histopathological analysis of papillary thyroid carcinoma detected during ultrasound screening examinations in Fukushima. Cancer Sci 110:817-827, 2019.
PubMed
19) 鈴木眞一:検診発見での甲状腺癌の取り扱い 手術の適応. 日本内分泌・甲状腺外科学会雑誌 35:70-76, 2018.
 
20) Yamashita S, Suzuki S, Suzuki S, et al:Lessons from Fukushima:Latest findings of thyroid cancer after the Fukushima nuclear power plant accident. Thyroid 28:11-22, 2018.
PubMed
21) Mitsutake N, Fukushima T, Matsuse M, et al:BRAF(V600E) mutation is highly prevalent in thyroid carcinomas in the young population in Fukushima:a different oncogenic profile from Chernobyl. Sci Rep 5:16976, 2015.
 
22) Iwadate M, Mitsutake N, Matsuse M, et al:The Clinicopathological Results of Thyroid Cancer With BRAFV600E Mutation in the Young Popu-lation of Fukushima. J Clin Endocrinol Metab 105:e4328-e4336, 2020.
 
23) 福島県県民健康調査検討委員会甲状腺検査評価部会:第16回甲状腺検査評価部会配布資料, 2021. https://www.pref.fukushima.lg.jp/site/portal/kenkocyosa-kentoiinkai-b16.html
 
P.287 掲載の参考文献
1) Wu Z, McGoogan J:Characteristics of and Impor-tant Lessons From the Coronavirus Disease 2019(COVID-19) Outbreak in China. JAMA 323 (13):1239-1242, 2020.
 
2) Yue H, Bai X, Wang J, et al:Gansu Provincial Medical Treatment Expert Group of COVID-19. Clinical characteristics of coronavirus disease 2019 in Gansu province, China. Ann Palliat Med 9(4):1404-1412, 2020.
 
3) COVID-19 Clinical management:living guidance. 25 January 2021.
 
4) 新型コロナウイルス感染症 COVID-19 診療の手引き 第8.0版
 
5) 山川賢太郎, 藤本 陽, 宮本和慶, 他:イムノクロマト法を用いた新型コロナウイルス SARS-CoV-2 抗原検出試薬の開発. 医学と薬学 77(6):937-944, 2020.
Medical*Online
6) 新型コロナウイルス感染症(COVID-19)病原体検査の指針 第5.1版
 
7) Yoshitomo Morinaga, Hiroshi Yamada, Yoshihiro Yoshida, et al:Analytical sensitivity of six lateral flow antigen test kits for variant strains of SARS-CoV-2. Journal of Infection and Chemotherapy 29(2):131-135, 2023.
PubMed
8) 佐野剛史, 菊池 眸, 高橋加奈子, 他:新型コロナウイルス迅速抗原検査キットの比較検討. 医学と薬学 78(5):627-632, 2021.
Medical*Online
9) 佐野剛史, 菊池 眸, 高橋加奈子, 他:新型コロナウイルスおよびインフルエンザウイルス同時検出迅速抗原検査キットの評価. 医学と薬学 78(12):1553-1560, 2021.
Medical*Online
10) Yang De Marinis, Anne-Katrine Pesola, Anna Soderlund Strand, et al:Detection of SARS-CoV-2 by rapid antigen tests on saliva in hospitalized patients with COVID-19. Infection Ecology & Epi-demiology 11(1):1993535, 2021.
 
11) Sabrina Jegerlehner, Franziska Suter-Riniker, Philipp Jent, et al:Diagnostic accuracy of SARS-CoV-2 saliva antigen testing in a real-life clinical setting. Int J Infect Dis 119:38-40, 2022.
 
P.296 掲載の参考文献
1) Fang Liu, Lin Li, MengDa Xu, et al:Prognostic value of interleukin-6, C-reactive protein, and pro-calcitonin in patients with COVID-19. J Clin Virol 127:104370, 2020.
PubMed
2) Elena Aloisio, Mariia Chibireva, Ludovica Serafini, et al:A Comprehensive Appraisal of Labora-tory BiochemistryTests as Major Predictors of COVID-19 Severity. Arch Pathol Lab Med 144:1457-1464, 2020.
 
3) Alisa A. Mueller, Tomoyoshi Tamura, Conor P. Crowley, et al:Inflammatory Biomarker Trends Predict RespiratoryDecline in COVID-19 Patients. Cell Reports Medicine 1:100144, 2020.
PubMed
4) Giulia Bivona, Luisa Agnello, Marcello Ciaccio:Bio-markers for Prognosis and Treatment Response in COVID-19 Patients. Ann Lab Med 41(6):540-548, 2021.
 
5) Nathaniel R Smilowitz, Dennis Kunichoff, Michael Garshick, et al:C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J 42(23):2270-2279, 2021.
PubMed
6) Auclair Guy, Zegers Ingrid, Charoud-Got Jean, et al:The Certification of the Mass Concentration of C-Reactive Protein in Human Serum - Certified Reference Material ERM(R)-DA474/IFCC. Euro-pean Commission, Joint Research Centre, Institute for Reference Materials and Measurements, Geel, Belgium, 1-31, 2011.
 
7) 日本臨床検査標準協議会:日本における主要な臨床検査項目の共用基準範囲-解説と利用の手引き-20221001 改訂版, 2022.
 
8) 康 東天:臨床検査値の共用基準範囲の設定. 日本内科学会雑誌 102:3088-3095, 2013.
 
9) Malgorzata Rzychon, Ingrid Zegers, Heinz Schimmel:Analysis of the Physicochemical State of C-Reactive Protein in Different Preparations Including 2 Certified Reference Materials. Clinical Chem 56(9):1475-1482, 2010.
PubMed
10) Tarek Khreiss, Levente Jozsef, Lawrence A. Potempa, et al:Loss of pentameric symmetry in C-reactive protein induces interleukin-8 secretion through peroxynitrite signaling in human neutro-phils. Circ Res 97(7):690-697, 2005.
 
P.310 掲載の参考文献
1) 厚生労働省 2019年 国民生活基礎調査 https://www.mhlw.go.jp/toukei/saikin/hw/k-tyosa/k-tyosa19/index.html
 
2) 竹内武昭, 中尾睦宏, 野村恭子, 他:ストレス自覚度ならびに社会生活指標が腰痛・関節痛, 肩こりに及ぼす影響:都道府県別データの解析. 心身医学 47(2):103-110, 2007.
Medical*Online
3) 竹波祥代:テーピング原理を応用した機能性スポーツウェアの開発. 繊維製品消費科学 60(3):242-245, 2019.
 
4) 柳井久江:4 Steps エクセル統計 第4版. オーエムエス出版, 東京, 2015.
 
5) 丹羽靱負, 小室俊夫:遠赤外線放射体プラチナ電磁波繊維のヒト白血球機能および過酸化脂質形成反応への影響. 炎症 11(2):135-141, 1991.
Medical*Online
6) 江角弘道, 木村幸弘:トルマリン利用健康商品の生体に対する効果:心拍変動スペクトルによる検討. 島根県立看護短期大学紀要 9:63-67, 2004.
 
7) 鈴木 誠:立ち上がり動作におけるバランスをどう見るか. 理学療法学 48(4):453-459, 2021.
Medical*Online
8) 田中喜代次, 松尾知明, 蘇 りな, 他:<総説>テレワーク・自宅待機に伴う運動不足・体力低下・有所見率増高への対策. 筑波大学体育系紀要 44:13-21, 2021.
 
9) 落合孝則:パソコン作業者の健康管理 第1回:肩こり, 腰痛, 目の疲れ. 日本テレワーク学会誌 8(2):78-82, 2010.
 
10) 森本昌宏:<総説>肩こりの臨床-適切な診断と治療のために. 近畿大学医学雑誌 35(3-4):151-156, 2010.
 
P.314 掲載の参考文献
1) 小峰裕己(編):室内微生物汚染 ダニ・カビ完全対策, pp.9-12, p.24, pp.132-134, 株式会社井上書院, 東京, 2007.
 
2) 島野智之, 高久 元(編):ダニのはなし-人間との関わり-, pp.4-7, pp.117-118, 株式会社朝倉書店, 東京, 2016.
 

書評

最近チェックした商品履歴

Loading...